Walmart settles US government's opioid lawsuit, which sought billions, for US$50 million

Walmart reported that Sparky users, up 70% YoY, spend 40% more per order. Azoma advises brands to optimize for Sparky by improving visibility across earned media, brand websites, and retailer content, as Sparky's recommendations depend on these sources. Walmart's e-commerce grew 23% in Q2.

Walmart (WMT) agreed to a $50 million settlement with the U.S. Justice Department for allegedly filling invalid opioid prescriptions. The settlement resolves claims that Walmart pharmacies and compliance teams knowingly filled suspicious prescriptions. Walmart will also strengthen its controlled substance dispensing practices under a DEA agreement. WMT closed at $103.09, up 0.45%.

Walmart agreed to a $50M settlement over allegations its pharmacies illegally filled opioid prescriptions, violating the Controlled Substances Act. The DOJ accused Walmart of prioritizing sales over compliance. Walmart must establish a reporting hotline and monitor dispensing patterns.

Walmart agreed to pay $50 million to settle allegations that its pharmacies illegally filled invalid opioid prescriptions from 2013 to 2020. The settlement requires Walmart to monitor dispensing patterns and establish processes to address suspicious activity. The DOJ emphasized the importance of enforcing pharmacy obligations to combat the opioid epidemic.

Walmart agreed to a $50 million settlement for allegedly filling invalid opioid prescriptions. The Justice Department and DEA claimed Walmart's pharmacies and compliance team ignored red flags. Walmart will establish monitoring and reporting systems as part of the agreement.

Walmart (WMT) will pay $50M to settle a DOJ lawsuit alleging its pharmacies filled invalid opioid prescriptions. The settlement includes compliance measures but no liability admission. WMT stock closed 0.45% higher on Friday and traded flat after-hours.